Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1155/2016/3295618 http://scihub22266oqcxt.onion/10.1155/2016/3295618 C4842050!4842050!27144163     free     free     free       Biomed+Res+Int 2016 ; 2016 (ä): ä Nephropedia Template TP {{tp|p=27144163|t=2016. FSGS Recurrence in Adults after Renal Transplantation |pdf=|usr=}}{{27144163}} gab.com Text FSGS Recurrence in Adults after Renal Transplantation JO: Biomed Res Int http://www.kidney.de/pget.php?&tw=1&pmid=27144163 #FOAvip Recurrence of focal segmental glomerulosclerosis (FSGS) in the allograft occurs in 30?50% of patients, and it is associated with poor renal allograft survival. Major risk factors for recurrence are younger age at diagnosis, rapid progression to end-stage renal disease, white race, and the loss of previous allografts due to recurrence. Recent data support the hypothesis that circulating permeability factors play a crucial role in podocyte injury and progression of FSGS. Due to lack of controlled trials, the management of recurrent FSGS is inconsistent and highly empirical. Prophylactic and perioperative treatment with plasmapheresis and high-dose (intravenous) cyclosporine represent the main cornerstones of immunosuppressive therapy. In recent years, therapy with rituximab has shown promising results. Despite evidence of activation of the renin-angiotensin system (RAS) in recurrent FSGS and its association with progression, only limited data exist on the renoprotective role of RAS blockade in this setting. Further well designed studies are needed on pathogenesis risk factors and therapeutical options in FSGS and its recurrence after transplantation. Twit Text FOAVip FSGS Recurrence in Adults after Renal Transplantation ????Biomed Res Int http://www.kidney.de/pget.php?&tw=1&pmid=27144163 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27144163 #FOAvip English Wikipedia <ref>{{Cite pmid|27144163}}</ref> FSGS Recurrence in Adults after Renal Transplantation #MMPMID27144163 Rudnicki M Biomed Res Int 2016[]; 2016 (ä): ä PMID27144163show ga Recurrence of focal segmental glomerulosclerosis (FSGS) in the allograft occurs in 30?50% of patients, and it is associated with poor renal allograft survival. Major risk factors for recurrence are younger age at diagnosis, rapid progression to end-stage renal disease, white race, and the loss of previous allografts due to recurrence. Recent data support the hypothesis that circulating permeability factors play a crucial role in podocyte injury and progression of FSGS. Due to lack of controlled trials, the management of recurrent FSGS is inconsistent and highly empirical. Prophylactic and perioperative treatment with plasmapheresis and high-dose (intravenous) cyclosporine represent the main cornerstones of immunosuppressive therapy. In recent years, therapy with rituximab has shown promising results. Despite evidence of activation of the renin-angiotensin system (RAS) in recurrent FSGS and its association with progression, only limited data exist on the renoprotective role of RAS blockade in this setting. Further well designed studies are needed on pathogenesis risk factors and therapeutical options in FSGS and its recurrence after transplantation. äFSGS Recurrence in Adults after Renal Transplantation (epmc).pdf DeepDyve Pubget Overpricing